homepage-top-section

A fully human monoclonal antibody, Saphnelo targets subunit 1 of the type one interferon (type 1 IFN) receptor, blocking the type 1 IFN’s activity. It has been recommended

A once-weekly long-acting recombinant human growth hormone, somatrogon is intended for treating children from three years of age and adolescents experiencing growth disturbance because of inadequate secretion of

AbbVie’s subsidiary Allergan has announced the availability of FDA-approved eye drop, VUITY (pilocarpine HCl ophthalmic solution) 1.25%, by prescription in pharmacies across the US. VUITY is a once-a-day

Financial details of the deal have not been disclosed. This deal is part of Sanofi’s strategy to explore growth opportunities and build a vaccines pipeline. The transaction will

An interleukin-23 (IL-23) inhibitor, Risankizumab is intended to treat patients with Crohn’s disease who have shown insufficient response, lost response or are intolerant to biologic or conventional treatment.

Quell Therapeutics has raised $156m funding through an oversubscribed Series B funding round to advance its multi-modular engineered T regulatory (Treg) cell therapy pipeline and platform. SV Health

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the use of Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, in children

Health Canada has granted full approval to Janssen Pharmaceutical Companies of Johnson & Johnson’s single-dose Covid-19 vaccine for the disease prevention in people aged 18 years and above.

The first-in-class Trop-2-directed antibody-drug conjugate was approved for use on TNBC patients who have received at least two systemic therapies including one or more for advanced disease. The